PARD3 and gastric adenocarcinoma: As shown in Fig. 1A, PARD3 expression was significantly higher in cholangiocarcinoma (CHOL), Diffuse large B-cell lymphoma (DLBC), glioblastoma (GBM), kidney renal papillary cell carcinoma (KIRP), low-grade glioma (LGG), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), pancreatic adenocarcinoma (PAAD), stomach adenocarcinoma (STAD), testicular germ cell tumor (TGCT) and thymic carcinoma (THYM).